

THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE BILL

No. 1022 Session of
2005

INTRODUCED BY BOYD, DeWEESE, STERN, KOTIK, RUBLEY, TRUE, DALLY, TIGUE, HERSHEY, CALTAGIRONE, SHANER, PICKETT, LEH, R. MILLER, ROSS, HENNESSEY, FREEMAN, WALKO, GEIST, REICHLEY, DENLINGER, CAWLEY, BALDWIN, LEACH, E. Z. TAYLOR, MANDERINO, JAMES, SOLOBAY, GINGRICH, HICKERNELL, HARPER, GOODMAN, WILT, O'NEILL, NICKOL, YOUNGBLOOD, DeLUCA, ROHRER, ARMSTRONG, FABRIZIO, MACKERETH, SAYLOR, STETLER, B. SMITH, WATSON AND KILLION, MARCH 16, 2005

AS REPORTED FROM COMMITTEE ON HEALTH AND HUMAN SERVICES, HOUSE OF REPRESENTATIVES, AS AMENDED, JANUARY 24, 2006

AN ACT

1 Providing for long-term care patient access to pharmaceuticals;
2 and conferring powers and duties on the State Board of
3 Pharmacy AND THE LEGISLATIVE BUDGET AND FINANCE COMMITTEE. <—

4 The General Assembly of the Commonwealth of Pennsylvania
5 hereby enacts as follows:

6 Section 1. Short title.

7 This act shall be known and may be cited as the Long-Term
8 Care Patient Access to Pharmaceuticals Act.

9 Section 2. Legislative intent.

10 The General Assembly finds and declares as follows:

11 (1) A mechanism is to be provided whereby patients who
12 have the ability to acquire lower cost drugs through a
13 Federal or State program, any insurance benefit program or
14 provider or another entity, have access to those drugs if
15 they reside in a long-term care facility.

1 (2) The mechanism is to be provided by permitting the
2 pharmacy within the long-term care facility or which has a
3 contract with the long-term care facility to:

4 (i) receive the lower cost drugs from the Federal or
5 State program, insurance program or provider or other
6 entity; and

7 (ii) repackage and relabel those drugs so they may
8 be dispensed in unit doses to patients in a long-term
9 care facility.

10 (3) This act shall be interpreted and construed to
11 effectuate the following purposes:

12 (i) To provide for the care, protection and
13 treatment of patients in long-term care facilities by
14 allowing them to utilize the drug benefit provided by the
15 Federal Government or State government, any insurance
16 program or provider or any other entity.

17 (ii) Consistent with the care, protection and
18 treatment of patients in long-term care facilities, to
19 provide a means by which a pharmacy in a long-term care
20 facility or a pharmacy which has a contract with a long-
21 term care facility may:

22 (A) accept, on behalf of the patient, drugs
23 received from a Federal or State program, any
24 insurance program or provider or another entity; and

25 (B) repackage and relabel those drugs so that
26 the patient may receive them in a unit dose.

27 (iii) To provide a means through which the
28 provisions of this act are executed and enforced and in
29 which long-term care facilities, pharmacists, drug source <—
30 ~~facilities~~ SOURCES and pharmaceutical providers may <—

1 implement the provisions of this act.

2 Section 3. Definitions.

3 The following words and phrases when used in this act shall
4 have the meanings given to them in this section unless the
5 context clearly indicates otherwise:

6 "Board." The State Board of Pharmacy.

7 "DISPENSE." AS RELATED TO A DRUG, TO PREPARE THE DRUG FOR
8 SUBSEQUENT ADMINISTRATION TO A PATIENT. THE TERM INCLUDES:

9 (1) THE ACT OF SCREENING THE DRUG FOR POTENTIAL DRUG
10 THERAPY PROBLEMS, INCLUDING REVIEWING POSSIBLE DRUG
11 INTERACTIONS, REVIEWING THE DOSAGE AND DURATION OF DRUG
12 THERAPY, REVIEWING CONTRAINDICATIONS OF THE DRUG, REVIEWING
13 INFORMATION REGARDING THE PATIENT AND PHARMACEUTICAL COVERAGE
14 AND COMPOUNDING AND MIXING THE DRUG; AND

15 (2) ANY OTHER ACTIVITY ASSOCIATED WITH REVIEW OF THE
16 DRUG WHICH IS DESIGNED TO ENSURE THE SAFETY OF THE DRUG.

17 "DRUG." MEDICATION WHICH HAS BEEN APPROVED BY THE FOOD AND
18 DRUG ADMINISTRATION. THE TERM DOES NOT INCLUDE MEDICATION WHICH
19 IS PROVIDED UNDER TITLE XVIII PT. D OF THE SOCIAL SECURITY ACT
20 (49 STAT. 620, 42 U.S.C. § 1395W-101 ET SEQ.).

21 ~~"Drug source facility." A facility where~~ SOURCE." A
22 FACILITY WHERE OR A PROGRAM UNDER WHICH drugs are lawfully
23 manufactured, dispensed or distributed. The term includes a
24 pharmacy, an entity and a Federal or State agency or
25 instrumentality. THE TERM DOES NOT INCLUDE A LONG-TERM CARE
26 PHARMACY.

27 "Long-term care facility." A long-term care nursing facility
28 as defined in section 802.1 of the act of July 19, 1979
29 (P.L.130, No.48), known as the Health Care Facilities Act.

30 "LONG-TERM CARE PHARMACY." ANY OF THE FOLLOWING:

1 (1) A PHARMACY WITHIN A LONG-TERM CARE FACILITY.

2 (2) A PHARMACIST EMPLOYED BY A LONG-TERM CARE FACILITY
3 WHO FILLS PRESCRIPTIONS FOR PATIENTS OF A LONG-TERM CARE
4 FACILITY.

5 (3) A PHARMACIST WHO CONTRACTS WITH A LONG-TERM CARE
6 FACILITY TO FILL PRESCRIPTIONS FOR PATIENTS OF A LONG-TERM
7 CARE FACILITY.

8 (4) A PHARMACEUTICAL PROVIDER THAT CONTRACTS WITH A
9 LONG-TERM CARE FACILITY TO FILL PRESCRIPTIONS FOR PATIENTS OF
10 A LONG-TERM CARE FACILITY.

11 "Pharmaceutical provider." An entity that employs a
12 pharmacist.

13 Section 4. State Board of Pharmacy.

14 The board has the following powers and duties:

15 ~~(1) Develop the form required by section 5(b)(3) and (4)~~ <—
16 ~~(relating to third party drugs in long term care facilities).~~

17 ~~(2) Promulgate regulations to set the fee under section~~
18 ~~7 (relating to fee). Included in this rulemaking, the board~~
19 ~~shall make a statement that the forms under paragraph (1)~~
20 ~~have been developed.~~

21 (1) WITHIN 90 DAYS OF THE EFFECTIVE DATE OF THIS <—
22 PARAGRAPH, DEVELOP THE FORM REQUIRED BY SECTION 5(C)(1)(III)
23 AND (2)(III) AND (E).

24 (2) DISTRIBUTE THE FORM, UPON REQUEST, TO LONG-TERM CARE
25 FACILITIES, PHYSICIANS, LONG-TERM CARE PHARMACIES,
26 PHARMACISTS AND THE PUBLIC.

27 (3) MAKE THE FORM AVAILABLE ELECTRONICALLY VIA THE
28 INTERNET.

29 ~~(3)~~ (4) Provide a written report every ~~90~~ 30 days <—
30 regarding the steps taken by the board to implement

paragraphs (1) and ~~(2)~~ (3), to all of the following:

<—

(i) The Consumer Protection and Professional
Licensure Committee of the Senate.

(ii) The Professional Licensure Committee of the
House of Representatives.

(iii) The Commissioner of the Bureau of Professional
and Occupational Affairs.

(iv) The Secretary of the Commonwealth.

~~Section 5. Third party drugs in long term care facilities.~~

<—

~~(a) Authority. Notwithstanding any other provision of law,
all of the following may dispense a drug acquired from a drug
source facility outside the long term care facility to a patient
of a long term care facility:~~

~~(1) A pharmacist employed by a long term care facility.~~

~~(2) A pharmacist who contracts with a long term care
facility to fill prescriptions for patients of the long term
care facility.~~

~~(3) A pharmaceutical provider that contracts with a
long term care facility to fill prescriptions for patients of
the long term care facility.~~

~~(b) Unit dose. A person authorized under subsection (a) to
dispense a drug shall repack, relabel and dispense the drug
in a unit dose if all of the following conditions are met:~~

~~(1) The drug is obtained from a drug source facility.~~

~~(2) There is a prescription for the drug.~~

~~(3) The prescriber has signed a form authorizing the
long term care facility to administer a drug from a drug
source facility outside the long term care facility.~~

~~(4) The patient has signed a form authorizing the long
term care facility to administer a drug from a drug source~~

~~facility outside the long term care facility. In the case of a minor or a patient who is unable to sign the form, a parent, a guardian, an agent acting under a power of attorney or a family member is authorized to sign the form. The form must explain that a person authorized under subsection (a) to dispense a drug from a drug source facility outside the long term care facility:~~

~~(i) is required to go through the process of repackaging and relabeling the drug;~~

~~(ii) may charge a fee for repackaging and relabeling the drug, including the amount of the fee and the frequency of its assessment; and~~

~~(iii) has immunity from civil liability arising from dispensation of the drug if the person properly repackages and relabels the drug as set forth in section 8 (relating to civil liability and unprofessional conduct).~~

SECTION 5. AUTHORIZATION TO ADMINISTER AND DISPENSE DRUGS
OBTAINED OUTSIDE OF LONG-TERM CARE PHARMACY.

(A) LONG-TERM CARE FACILITIES.--NOTWITHSTANDING ANY OTHER PROVISION OF LAW TO THE CONTRARY, A LONG-TERM CARE FACILITY MAY ADMINISTER A DRUG ACQUIRED FROM A DRUG SOURCE TO A PATIENT OF A LONG-TERM CARE FACILITY.

(B) LONG-TERM CARE PHARMACIES.--NOTWITHSTANDING ANY OTHER PROVISION OF LAW TO THE CONTRARY, A LONG-TERM CARE PHARMACY MAY DISPENSE A DRUG ACQUIRED FROM A DRUG SOURCE FOR ADMINISTRATION TO A PATIENT OF A LONG-TERM CARE FACILITY.

(C) PROVISION OF DRUG TO PATIENT.--

(1) A LONG-TERM CARE FACILITY SHALL ADMINISTER A DRUG ACQUIRED FROM A DRUG SOURCE TO A PATIENT OF A LONG-TERM CARE

1 FACILITY IF ALL OF THE FOLLOWING CONDITIONS ARE MET:

2 (I) THE DRUG IS ACQUIRED FROM A DRUG SOURCE.

3 (II) THERE IS A PRESCRIPTION FOR THE DRUG.

4 (III) THE PATIENT HAS SIGNED A FORM UNDER SUBSECTION
5 (E) AUTHORIZING THE LONG-TERM CARE FACILITY TO ADMINISTER
6 A DRUG ACQUIRED FROM A DRUG SOURCE. IN THE CASE OF A
7 MINOR OR PATIENT WHO IS UNABLE TO SIGN THE FORM, A
8 PARENT, GUARDIAN, AN AGENT ACTING UNDER A POWER OF
9 ATTORNEY OR A FAMILY MEMBER IS AUTHORIZED TO SIGN THE
10 FORM.

11 (2) A LONG-TERM CARE PHARMACY SHALL DISPENSE A DRUG
12 ACQUIRED FROM A DRUG SOURCE TO A PATIENT OF A LONG-TERM CARE
13 FACILITY IF ALL OF THE FOLLOWING CONDITIONS ARE MET:

14 (I) THE DRUG IS ACQUIRED FROM A DRUG SOURCE.

15 (II) THERE IS A PRESCRIPTION FOR THE DRUG.

16 (III) THE PATIENT HAS SIGNED A FORM UNDER SUBSECTION
17 (E) AUTHORIZING THE LONG-TERM CARE PHARMACY TO DISPENSE A
18 DRUG ACQUIRED FROM A DRUG SOURCE. IN THE CASE OF A MINOR
19 OR PATIENT WHO IS UNABLE TO SIGN THE FORM, A PARENT,
20 GUARDIAN, AN AGENT ACTING UNDER A POWER OF ATTORNEY OR A
21 FAMILY MEMBER IS AUTHORIZED TO SIGN THE FORM.

22 (D) UNIT DOSE.--A LONG-TERM CARE PHARMACY SHALL REPACKAGE,
23 RELABEL AND DISPENSE A DRUG ACQUIRED FROM A DRUG SOURCE IN UNIT
24 DOSES OR SUCH OTHER FORMS AS TO ENABLE A LONG-TERM CARE FACILITY
25 TO ADMINISTER THE DRUG TO A PATIENT SAFELY AND IN A MANNER AND
26 FORM THAT CONFORM WITH THE LONG-TERM CARE FACILITY'S DRUG
27 ADMINISTRATION PROCEDURES AND QUALITY ASSURANCE STANDARDS.

28 (E) CONTENTS OF FORM.--AN AUTHORIZATION UNDER SUBSECTION
29 (C)(1)(III) AND (2)(III) MUST EXPLAIN THAT A LONG-TERM CARE
30 PHARMACY:

(1) IS REQUIRED TO GO THROUGH THE PROCESS OF DISPENSING, REPACKAGING AND RELABELING THE DRUG SO THAT THE DRUG MAY BE ADMINISTERED SAFELY AND IN A MANNER AND FORM THAT CONFORM TO THE LONG-TERM CARE FACILITY'S DRUG ADMINISTRATION PROCEDURES AND QUALITY ASSURANCE STANDARDS;

(2) MAY CHARGE A REASONABLE FEE WHICH MAY NOT EXCEED THE LIMIT SET FORTH IN SECTION 7(C) WHICH MAY BE CHARGED TO THE PATIENT FOR COSTS ASSOCIATED WITH DISPENSING, REPACKAGING AND RELABELING THE DRUG;

(3) IS REQUIRED TO DISCLOSE THE AMOUNT OF THE FEE, AND THAT THE FEE MAY BE CHARGED FOR EACH DRUG DISPENSED; AND

(4) IS IMMUNE FROM CIVIL LIABILITY ARISING FROM HARM CAUSED BY THE DRUG DUE TO ACTS OR OMISSIONS OF OTHER PERSONS OUTSIDE OF THE LONG-TERM CARE PHARMACY IF THE LONG-TERM CARE PHARMACY PROPERLY DISPENSES, REPACKAGES AND RELABELS THE DRUG.

(F) TEMPORARY FORM.--A LONG-TERM CARE FACILITY MAY DEVELOP THE FORM REQUIRED UNDER SUBSECTIONS (C)(1)(III) AND (2)(III) AND (E) AND USE THE FORM UNTIL THE BOARD DEVELOPS A FORM UNDER SECTION 4.

Section 6. Recordkeeping.

~~For each drug dispensed in accordance with section 5(a) (relating to third party drugs in long term care facilities), the person authorized to dispense the drug and the long term~~

FOR EACH DRUG DISPENSED BY A LONG-TERM CARE PHARMACY UNDER SECTION 5(B) AND (C)(2), THE LONG-TERM CARE PHARMACY AND THE LONG-TERM care facility shall maintain a record for at least two years of all of the following:

(1) The name and quantity of the drug prescribed, including whether the prescription is a controlled substance

or if it was written PRN or ad lib refill.

(2) The name and address of the patient to whom it was dispensed.

(3) The name and address or other identifier of the prescriber.

(4) The date the prescription was issued and the date the drug was dispensed.

(5) Directions for use, including cautions communicated to the patient by auxiliary labels or other means when dispensed.

(6) The date the prescription was compounded or dispensed.

(7) The name and address of the dispensing pharmacist.

(8) The drug source facility which provided the drug.

~~Section 7. Fee.~~

~~A person authorized under 5(a) (relating to third party drugs in long term care facilities) to dispense a drug may charge a reasonable fee, set by the board, to repackage and relabel the drug.~~

~~Section 8. Civil liability and unprofessional conduct.~~

~~(a) Repackaging and relabeling. A person authorized under section 5(a) (relating to third party drugs in long term care facilities) to dispense a drug shall be immune from civil liability arising out of dispensation of the drug if the person properly repackages and relabels a drug.~~

~~(b) Administration of drug. A long term care facility or an employee or agent of a long term care facility that properly administers a drug from a person authorized under section 5(a) to dispense the drug shall be immune from civil liability arising out of administration of the drug.~~

~~(c) Unprofessional conduct. A pharmacist authorized under section 5(a)(3) to dispense a drug who properly relabels and repackages the drug shall not be deemed to have engaged in unprofessional conduct under section 5 of the act of September 27, 1961 (P.L.1700, No.699), known as the Pharmacy Act.~~

~~Section 40. Effective date.~~

~~This act shall take effect as follows:~~

~~(1) The following provisions shall take effect upon publication of the rulemaking in the Pennsylvania Bulletin under section 4(2):~~

~~(i) Section 5.~~

~~(ii) Section 7.~~

~~(2) The remainder of this act shall take effect immediately.~~

SECTION 7. FEE.

(A) FEE AUTHORIZED.--A LONG-TERM CARE PHARMACY AUTHORIZED UNDER SECTION 5 TO DISPENSE A DRUG ACQUIRED FROM A DRUG SOURCE MAY CHARGE A REASONABLE FEE FOR EACH DRUG AS SET FORTH IN SUBSECTION (C) TO THE PATIENT OF A LONG-TERM CARE FACILITY.

(B) REPORT TO THE BOARD.--THE LONG-TERM CARE PHARMACY SHALL REPORT THE AMOUNT OF THE FEE TO THE BOARD. A CHANGE IN THE FEE SHALL BE REPORTED TO THE BOARD WITHIN TEN BUSINESS DAYS.

(C) DETERMINATION OF FEE.--A FEE IS REASONABLE IF THE FEE DOES NOT EXCEED AN AMOUNT WHICH IS FOUR TIMES THE SPECIFIC DOLLAR AMOUNT OF THE PROGRAM PAYMENT UNDER SECTION 509(6)(III) OF THE ACT OF AUGUST 26, 1971 (P.L.351, NO.91), KNOWN AS THE STATE LOTTERY LAW.

SECTION 8. IMMUNITY AND UNPROFESSIONAL CONDUCT.

(A) LONG-TERM CARE PHARMACIES.--A LONG-TERM CARE PHARMACY AUTHORIZED UNDER SECTION 5 TO DISPENSE A DRUG ACQUIRED FROM A

1 DRUG SOURCE SHALL BE IMMUNE FROM CIVIL LIABILITY ARISING FROM
2 HARM CAUSED BY THE DRUG DUE TO ACTS OR OMISSIONS OF OTHER
3 PERSONS OUTSIDE OF THE LONG-TERM CARE PHARMACY IF THE LONG-TERM
4 CARE PHARMACY PROPERLY DISPENSES, REPACKAGES AND RELABELS THE
5 DRUG.

6 (B) LONG-TERM CARE FACILITIES.--

7 (1) A LONG-TERM CARE FACILITY THAT PROPERLY ADMINISTERS
8 A DRUG PROVIDED BY A LONG-TERM CARE PHARMACY UNDER SECTION 5
9 SHALL BE IMMUNE FROM CIVIL LIABILITY ARISING FROM HARM CAUSED
10 BY THE DRUG DUE TO ACTS OR OMISSIONS OF OTHER PERSONS OUTSIDE
11 THE LONG-TERM CARE FACILITY.

12 (2) AN EMPLOYEE OR AGENT OF A LONG-TERM CARE FACILITY
13 WHO PROPERLY ADMINISTERS A DRUG PROVIDED BY A LONG-TERM CARE
14 PHARMACY UNDER SECTION 5 SHALL BE IMMUNE FROM CIVIL LIABILITY
15 ARISING FROM HARM CAUSED BY THE DRUG DUE TO ACTS OR OMISSIONS
16 OF OTHER PERSONS OUTSIDE THE LONG-TERM CARE FACILITY.

17 (C) UNPROFESSIONAL CONDUCT.--A PHARMACIST WHO PROPERLY
18 DISPENSES, REPACKAGES AND RELABELS A DRUG ACQUIRED FROM A DRUG
19 SOURCE UNDER SECTION 5 SHALL NOT BE DEEMED TO HAVE ENGAGED IN
20 UNPROFESSIONAL CONDUCT UNDER SECTION 5 OF THE ACT OF SEPTEMBER
21 27, 1961 (P.L.1700, NO.699), KNOWN AS THE PHARMACY ACT.
22 SECTION 9. RELATION TO PHARMACY ACT.

23 (A) PREVENTION OR PROHIBITION.--NOTHING IN THE ACT OF
24 SEPTEMBER 27, 1961 (P.L.1700, NO.699), KNOWN AS THE PHARMACY
25 ACT, SHALL BE CONSTRUED TO PREVENT OR PROHIBIT ANY OF THE
26 FOLLOWING FROM COMPLYING WITH THE PROVISIONS OF THIS ACT:

27 (1) A PHARMACIST.

28 (2) A PHARMACY, AS DEFINED IN SECTION 2(12) OF THE
29 PHARMACY ACT.

30 (B) CONFLICT.--IF THERE IS A CONFLICT BETWEEN A PROVISION OF

1 THE PHARMACY ACT AND A PROVISION OF THIS ACT, THE PROVISION OF
2 THIS ACT SHALL PREVAIL.

3 SECTION 10. STUDY BY LEGISLATIVE BUDGET AND FINANCE COMMITTEE.

4 (A) STUDY COMMISSIONED.--ONE YEAR AFTER THE EFFECTIVE DATE
5 OF THIS SECTION, THE LEGISLATIVE BUDGET AND FINANCE COMMITTEE
6 SHALL COMMENCE A STUDY OF THE FOLLOWING:

7 (1) THE EFFECTIVENESS OF THIS ACT WITH RESPECT TO
8 PATIENTS IN LONG-TERM CARE FACILITIES RECEIVING LOWER-COST
9 PHARMACEUTICALS.

10 (2) THE EXPERIENCE OF PATIENTS, LONG-TERM CARE
11 FACILITIES AND LONG-TERM CARE PHARMACIES AUTHORIZED UNDER
12 SECTION 5 TO DISPENSE A DRUG ACQUIRED FROM A DRUG SOURCE,
13 WITH RESPECT TO COMPLYING WITH THE PROVISIONS OF THIS ACT.

14 (3) THE SUFFICIENCY OF THE RECORDKEEPING REQUIREMENTS
15 SET FORTH IN SECTION 6 WITH RESPECT TO ASSURING PATIENT
16 SAFETY, PREVENTING DIVERSION OF DRUGS AND ASSURING THE
17 QUALITY OF DRUGS.

18 (B) REPORT AND RECOMMENDATIONS.--THE COMMITTEE SHALL MAKE A
19 REPORT OF ITS FINDINGS AND RECOMMENDATIONS WITHIN TWO YEARS OF
20 THE EFFECTIVE DATE OF THIS SECTION TO THE PRESIDENT PRO TEMPORE
21 OF THE SENATE, THE SPEAKER OF THE HOUSE OF REPRESENTATIVES, THE
22 CONSUMER PROTECTION AND PROFESSIONAL LICENSURE COMMITTEE OF THE
23 SENATE AND THE PROFESSIONAL LICENSURE COMMITTEE OF THE HOUSE OF
24 REPRESENTATIVES.

25 SECTION 40. EFFECTIVE DATE.

26 THIS ACT SHALL TAKE EFFECT IN 60 DAYS.